ATC codes:
L01XA02
EMLc
Indication
Retinoblastoma
ICD11 code:
2D52.2
INN
Carboplatin
Medicine type
Chemical agent
List type
Complementary
(EML)
(EMLc)
(EMLc)
Formulations
Parenteral > General injections > IV:
50 mg per 5 mL ;
150 mg per 15 mL ;
450 mg per 45 mL ;
600 mg per 60 mL
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer.
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML and EMLc for use in treatment protocols for retinoblastoma was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of the treatment protocols for retinoblastoma is attached.